U.S. markets open in 2 hours 57 minutes
  • S&P Futures

    4,076.00
    -8.75 (-0.21%)
     
  • Dow Futures

    32,553.00
    -28.00 (-0.09%)
     
  • Nasdaq Futures

    12,507.00
    -53.25 (-0.42%)
     
  • Russell 2000 Futures

    1,831.00
    -6.20 (-0.34%)
     
  • Crude Oil

    113.88
    +1.48 (+1.32%)
     
  • Gold

    1,817.00
    -1.90 (-0.10%)
     
  • Silver

    21.72
    -0.03 (-0.14%)
     
  • EUR/USD

    1.0526
    -0.0029 (-0.27%)
     
  • 10-Yr Bond

    2.9680
    0.0000 (0.00%)
     
  • Vix

    26.32
    -1.15 (-4.19%)
     
  • GBP/USD

    1.2416
    -0.0076 (-0.61%)
     
  • USD/JPY

    129.0830
    -0.2750 (-0.21%)
     
  • BTC-USD

    30,006.72
    -555.66 (-1.82%)
     
  • CMC Crypto 200

    673.89
    +431.21 (+177.69%)
     
  • FTSE 100

    7,520.98
    +2.63 (+0.03%)
     
  • Nikkei 225

    26,911.20
    +251.45 (+0.94%)
     

See why Craig-Hallum Is Bullish On iSpecimen

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Craig-Hallum initiated coverage of iSpecimen Inc (NASDAQ: ISPC) with a Buy rating and $20 price target.

  • "Much the way Amazon has become the go-to platform for buyers and sellers of consumer goods," the analyst believes iSpecimen can become the go-to platform for human biospecimens, writes analyst Matthew Hewitt.

  • The analyst notes that though the Company was founded in 2009, it has only recently reached a critical mass of buyers and sellers, with revenue for 2021 on track to be nearly triple the 2019 level.

  • Related: iSpecimen Stock Rallies On Supply Pact Of Human Biospecimens For COVID-19 Research.

  • The Company offers a range of biofluids, tissue, and stem and immune cells, including specimens with genetic variants (such as COVID-19 variants).

  • Recently, iSpecimen expanded its global supplier network, with 25% of its newest specimen suppliers in 2021 coming from outside the U.S.

  • Throughout 2021, iSpecimen has added nearly two dozen biospecimen suppliers to its network across the U.S., Europe, and Asia-Pacific.

  • In December, iSpecimen expanded its global biospecimen provider network to support research related to neurological disorders.

  • Price Action: ISPC shares are up 7.20 at $8.64 during the market session on the last check Tuesday.

Latest Ratings for ISPC

Jan 2022

Craig-Hallum

Initiates Coverage On

Buy

Nov 2021

EF Hutton

Maintains

Buy

View More Analyst Ratings for ISPC
View the Latest Analyst Ratings

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.